ArticleAnnals of clinical and translational neurology2026
Remarkable Recovery After Delayed High-Dose Methylprednisolone in a Rare Case of Penetrating Spinal Cord Injury.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remarkable Recovery After Delayed High-Dose Methylprednisolone in a Rare Case of Penetrating Spinal Cord Injury.Annals of clinical and translational neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic spinal cord injury (TSCI) caused by sharp-force penetration is exceptionally rare, and the use of high-dose methylprednisolone (MP) remains highly controversial, especially beyond the conventional 8-h treatment window. This case report describes a 30-year-old male with acute incomplete TSCI following a knife stab wound to the right neck. Despite no initial improvement, high-dose MP (1000 mg/day for 3 days, tapered thereafter) was initiated 40 h post-injury, along with mannitol. Remarkable neurological recovery was observed, including independent ambulation by post-injury day 25. Follow-up MRI showed significant hematoma absorption. This case suggests that delayed high-dose MP may benefit selected TSCI patients, particularly those with penetrating mechanisms and ongoing secondary injury. It highlights the potential for extending the therapeutic window in specific scenarios and supports the need for further research into individualized treatment strategies for TSCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.